Eli Lilly and Company and AC Immune have signed an agreement for the research and development of tau aggregation inhibitor small molecules, and AC Immune signed a strategic partnership with WuXi biologics.
Researchers are using artificial intelligence to catalyze drug discovery and preclinical drug development - improving predictive models to guide efficient design and optimizing multi-drug regimens, as two recent examples.
Exelixis has submitted an investigational new drug application
(IND) to the US Food and Drug Administration (FDA) for XL820, a
novel small molecule anticancer compound that inhibits receptor
tyrosine kinases (RTKs) implicated in tumour...
A new therapeutic technique based on a small molecule working in
tandem with a larger protein has been shown to block accumulation
of the brain-clogging amyloid protein seen in Alzheimer's disease,
raising the possibility of...
A US company is gearing up to start trials of a novel drug that
could provide the first orally-active treatment for a range of
genetic disorders, including cystic fibrosis and muscular
dystrophy, writes Phil Taylor.